Finally out in @ScienceMagazine! Utilizing the cost-effective EasySci to profile 21 million single-cell transcriptomes across five life stages and diverse sexes/genotypes, we reveal aging as distinct, development-like transitions, with dramatic cell population changes in specific

I’m excited to share our latest study in @nature on this novel compound called Gliocidin, that targets glioblastoma (#GBM), the most malignant brain tumor. #drugdiscovery #cancer #cancermetabolism @GSKGradSchool @MSKCancerCenter https://t.co/MbViHc7INS

Check out our latest paper integrating genomic and functional precision medicine to identify therapeutic vulnerabilities in glioblastoma https://t.co/Xka3S4XdB2

Incredible team effort on this translational project - just in time for SNO! Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses

Our work reveals that as IDH mutant gliomas progress, their cell states and key drivers change.

#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief. “There’s a

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas | Nature

One of the major challenges in human genomics is the functional assessment of variants. Base and prime #CRISPR genome editing is making a big difference for meeting that challenge, as exemplified in this new report @NatureBiotech https://t.co/he8oGniSrM @randall_platt

Enhancing transcription–replication conflict targets ecDNA-positive cancers | Nature

ecDNA are rogue genetic material that amplify genes, contribute to treatment resistance and drive genomic heterogeneity. We report on the Origins and impact of extrachromosomal DNA today in @Nature

Today #CancerGrandChallenges team eDyNAmiC and their international collaborators published 3️⃣ papers in @Nature 📣 They show the prevalence of ecDNA in cancer, identify fundamental mechanisms and an actionable target now being tested in the clinic. More: https://t.co/lx5dtVlyDK

Thrilled to share our paper published in @Nature, where we uncover a new process of tumor initiation through a polyclonal-to-monoclonal transition at the @precancerous stage. So proud of my fantastic team (led by @ZhaolianLu ) and incredible collaborators! https://t.co/ARx7aH7Vgq

First of a series of papers from the @NCIHTAN is out in @Nature this morning. Tumour evolution and microenvironment interactions in 2D and 3D space https://t.co/dZGqvbTgMt

🚨 Great alternatives to BioRender are now available!! 📢 @NIAIDNews offers a collection of public figures and icons for everyone to use. Check it out at https://t.co/cZFQAf5nTz

Because ONE spatial profiling technology is not enough! New paper by @Nikhilwagle in @NatureMedicine A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features https://t.co/7OGk3LsZUF Dissociated single

Transforming traditional views laid by “CNS immune privilege,” our research uncovers the brain’s purposeful presentation of self – that is the brain engages with the immune system through “guardian” peptides to ensure immune tolerance. @jonykipnis https://t.co/XRr11LC82M

Huge congratulations to @KarunaMDPhD for this important study out in @Nature Progressive plasticity during colorectal cancer metastasis https://t.co/9lmfr2SKSg Many orthogonal patient-derived models, and an important lesson here for all: "The non-canonical states that we

The tumor microenvironment of SCLC is often "immune cold" (due to low T cell infiltration & high immune suppression), & frequently shows high levels of DNA damage response. Despite these complexities, new clinical targets are now demonstrating promising activity: DLL3, B7H3,

IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation